4-吡咯烷-1-基甲基苄胺 | 91271-79-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-吡咯烷-1-基甲基苄胺
• 中文别名: 4-吡咯烷-1-甲基苄胺
• 英文名称: (4-(pyrrolidin-1-ylmethyl)phenyl)methylamine
• 英文别名: 4-Pyrrolidin-1-ylmethyl-benzylamine；[4-(pyrrolidin-1-ylmethyl)phenyl]methanamine
• CAS: 91271-79-3
• 化学式: C₁₂H₁₈N₂
• mdl: MFCD07329913
• 分子量: 190.288
• InChiKey: XSJFYCYUKSAOIY-UHFFFAOYSA-N

物化性质

• 沸点：
  120-125/0.5mm
• 密度：
  1.068±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  C

反应信息

• 作为反应物：
  描述：

  4-吡咯烷-1-基甲基苄胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 7-nitro-3-(4-(pyrrolidin-1-ylmethyl)benzyl)quinazolin-4(3H)-one
  参考文献：
  名称：

  Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines and Quinazolines as Potential Antimalarial Agents

  摘要：

  The intramolecular hydrogen bond formed between a protonated amine and a neighboring H-bond acceptor group in the side chain of amodiaquine and isoquine is thought to play an important role in their antimalarial activities. Here we describe isoquine-based compounds in which the intramolecular H-bond is mimicked by a methylene linker. The antimalarial activities of the resulting benzoxazines, their isosteric tetrahydroquinazoline derivatives, and febrifugine-based 1,3-quinazolin-4-ones were examined in vitro (against Plasmodium falciparum) and in vivo (against Plasmodium berghei). Compounds 6b,c caused modest inhibition of chloroquine transport via the parasite's "chloroquine resistance transporter" (PfCRT) in a Xenopus laevis oocyte expression system. In silico predictions and experimental evaluation of selected drug-like properties were also performed on compounds 6b,c. Compound 6c emerged from this work as the most promising analogue of the series; it possessed low toxicity and good antimalarial activity when administered orally to P. berghei-infected mice.

  DOI：

  10.1021/jm300831b
• 作为产物：
  描述：

  4-(pyrrolidin-1-ylmethyl)benzonitrile 在 硼烷四氢呋喃络合物 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 4-吡咯烷-1-基甲基苄胺
  参考文献：
  名称：

  Compounds

  摘要：

  本申请中披露和声明了通式I的化合物，以及它们的药用盐，包含这些新化合物的药物组合物以及它们在治疗中的使用，特别是在疼痛管理方面。

  公开号：

  US06777561B1

文献信息

• SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS
  申请人：Herdewijn Piet André Maurits Maria

  公开号：US20090318456A1

  公开（公告）日：2009-12-24

  Tri-substituted pteridines and tetra-substituted pteridines exhibit a significant and selective activity against certain types of viral infections, in particular they selectively inhibit the replication of the hepatitis C virus, and are useful for the prevention and treatment of such infections.

  三取代喹啉和四取代喹啉对某些类型的病毒感染表现出显著和选择性的活性，特别是它们选择性地抑制丙型肝炎病毒的复制，并可用于预防和治疗此类感染。
• SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS
  申请人：Herdewijn Piet Andre' Maurits Maria

  公开号：US20090253696A1

  公开（公告）日：2009-10-08

  This invention provides di-, tri- and tetra-substituted pyrido(3,2-d)pyrimidine derivatives with specific substituting patterns, their pharmaceutically acceptable salts, N-oxides, solvates, pro-drugs and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular being highly active antiviral agents. The invention also provides use of such derivatives in the treatment of viral infections and pathologic conditions associated therewith, including hepatitis C.

  这项发明提供了具有特定取代模式的二、三和四取代吡啶并[3,2-d]嘧啶衍生物，其药学上可接受的盐、N-氧化物、溶剂合物、前药和对映体，具有意外地理想的药理特性，特别是作为高活性抗病毒剂。该发明还提供了利用这些衍生物治疗病毒感染及相关病理状况，包括丙型肝炎的用途。
• [EN] NEW BRADYKININ B1 ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DU RÉCEPTEUR DE LA BRADYKININE B1
  申请人：EVOTEC NEUROSCIENCES GMBH

  公开号：WO2010020556A1

  公开（公告）日：2010-02-25

  The invention relates to compounds of formula (I) wherein R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  该发明涉及式（I）的化合物，其中R1、R1a、R1b、R2、R3以及X、X1、X2、X3的含义如描述和权利要求中所述。所述化合物可用作Bradykinin B1拮抗剂。该发明还涉及制药组合物、该类化合物的制备以及作为药物的生产和使用。
• Compounds for the treatment of inflammatory diseases
  申请人：Hoenke Christoph

  公开号：US20070259846A1

  公开（公告）日：2007-11-08

  Dihydrothienopyrimidines of formula 1 and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  化学式1的二氢噻吡嘧啶及其药理学上可接受的盐、对映体、消旋体、水合物或溶剂合物，适用于治疗呼吸道或胃肠道不适或疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症，以及含有这些化合物的药物组合物。
• [EN] SULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE SULFONAMIDE EN TANT QU'INHIBITEURS DE STAT3 POUR LE TRAITEMENT DE MALADIES PROLIFÉRANTES
  申请人：KING S COLLEGE LONDON

  公开号：WO2019030538A1

  公开（公告）日：2019-02-14

  The invention relates to derivatives of formula (I) where R1, R2, R3, R4, R5, X and m are as defined in the specification. These compounds which have therapeutic activity, in particular, as STAT3 inhibitors and so are useful in the treatment of proliferative diseases or conditions such as cancer. Methods for producing these compounds, novel intermediates used in the methods, pharmaceutical compositions containing them and their use in therapy form further aspects of the invention.

  该发明涉及到公式(I)的衍生物，其中R1、R2、R3、R4、R5、X和m的定义如规范中所述。这些化合物具有治疗活性，特别是作为STAT3抑制剂，在治疗增殖性疾病或状况，如癌症方面具有用途。制备这些化合物的方法，方法中使用的新型中间体，含有它们的药物组合物以及它们在治疗中的使用等方面也是该发明的进一步方面。